MA28116A1 - Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan - Google Patents

Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan

Info

Publication number
MA28116A1
MA28116A1 MA28976A MA28976A MA28116A1 MA 28116 A1 MA28116 A1 MA 28116A1 MA 28976 A MA28976 A MA 28976A MA 28976 A MA28976 A MA 28976A MA 28116 A1 MA28116 A1 MA 28116A1
Authority
MA
Morocco
Prior art keywords
insulin
secretagogue
fatty acid
acid ester
polyoxyethylene sorbitan
Prior art date
Application number
MA28976A
Other languages
English (en)
Inventor
Kazuhiro Doken
Tetsuya Kawano
Hiroyoshi Koyama
Naoru Hamaguchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34543966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA28116A1 publication Critical patent/MA28116A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA28976A 2003-10-31 2006-04-28 Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan MA28116A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003371679 2003-10-31

Publications (1)

Publication Number Publication Date
MA28116A1 true MA28116A1 (fr) 2006-08-01

Family

ID=34543966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28976A MA28116A1 (fr) 2003-10-31 2006-04-28 Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan

Country Status (28)

Country Link
US (1) US7700128B2 (fr)
EP (1) EP1677792B1 (fr)
KR (2) KR100952090B1 (fr)
CN (1) CN1874774B (fr)
AR (1) AR046210A1 (fr)
AU (1) AU2004285354B2 (fr)
BR (1) BRPI0414979A (fr)
CA (1) CA2540225C (fr)
CY (1) CY1117176T1 (fr)
DK (1) DK1677792T3 (fr)
ES (1) ES2556244T3 (fr)
GE (1) GEP20084570B (fr)
HR (1) HRP20151447T1 (fr)
HU (1) HUE028576T2 (fr)
IL (1) IL174201A (fr)
JO (1) JO3106B1 (fr)
MA (1) MA28116A1 (fr)
MX (1) MXPA06004639A (fr)
NO (1) NO340294B1 (fr)
NZ (1) NZ546337A (fr)
PE (1) PE20050923A1 (fr)
PL (1) PL1677792T3 (fr)
PT (1) PT1677792E (fr)
RU (1) RU2359661C2 (fr)
SI (1) SI1677792T1 (fr)
TW (1) TWI339586B (fr)
WO (1) WO2005041962A1 (fr)
ZA (1) ZA200602056B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034999A2 (fr) * 2003-10-10 2005-04-21 Bvm Holding Co. Composition pharmaceutique
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
AU2006328328B2 (en) * 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
TWI492747B (zh) 2006-06-27 2015-07-21 Daiichi Sankyo Co Ltd 壓縮製劑
MY147596A (en) * 2007-02-01 2012-12-31 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
IS8660A (is) * 2007-07-02 2009-01-03 Actavis Group Ptc Ehf. Gliklasíð lyfjasamsetning
WO2009120844A2 (fr) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Compositions pharmaceutiques comprenant un sensibilisateur à l’insuline et un secrétagogue d’insuline
CA2782776A1 (fr) 2008-12-04 2010-06-10 Ikfe Gmbh Marqueurs biologiques de l'atherosclerose
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
US20100209350A1 (en) 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
EP2382475A2 (fr) 2009-01-07 2011-11-02 IKFE GmbH Marqueurs biologiques pour la régulation de l'appétit
CA2754950A1 (fr) * 2009-03-20 2010-09-23 Smartcells, Inc. Conjugues fonctionnalises aux extremites et leurs utilisations
MX390695B (es) * 2010-09-21 2025-03-21 Intekrin Therapeutics Inc Composiciones farmaceuticas solidas antidiabeticas
EP2438911A1 (fr) 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Compositions pharmaceutiques comprenant du secrétagogue d'insuline de classe suphonylurée et huile de ricin à base de glycol de polyéthylène
WO2013034174A1 (fr) * 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Préparations solides de pioglitazone et de glimépiride
CN104288161A (zh) * 2014-09-19 2015-01-21 四川海思科制药有限公司 一种含吡格列酮格列美脲的药物组合物
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
LT3804714T (lt) 2018-05-31 2025-03-10 Hua Medicine (Shanghai) Ltd. Farmacinis derinys ir kompozicija, ir derinio preparatas, kurio sudėtyje yra gliukokinazės aktyvatorius ir biguanido hipoglikeminis vaistas, taip pat jų gamybos būdas ir panaudojimas

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5865213A (ja) * 1981-10-13 1983-04-18 Tokai Kapuseru Kk ｄｌ−２−（４，８，１２−トリメチルトリデシル）−２，５，７，８−テトラメチル−６−クロマニルニコチネ−ト軟カプセル剤
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
JP2764274B2 (ja) * 1988-03-28 1998-06-11 株式会社ミドリ十字 医薬組成物
ATE198547T1 (de) * 1993-11-03 2001-01-15 Isomed Inc Mizelleförmige feinteilige pharmazeutische zusammensetzungen
HU212428B (en) * 1994-05-13 1996-06-28 Egyt Gyogyszervegyeszeti Gyar Process to prepare pharmaceutical compositions containing gemfibrozyl
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
EP0811374A1 (fr) * 1996-05-29 1997-12-10 Pfizer Inc. Formulation d'une combinaison de cetirizine et pseudoephedrine
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
DE69837089T2 (de) * 1997-06-18 2007-06-21 Smithkline Beecham P.L.C., Brentford Behandlung der diabetes mit thiazolidindion und sulfonylharnstoff
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
CZ20011629A3 (cs) 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
CA2408913A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
CA2725833A1 (fr) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Systeme de liberation espacee de medicaments
WO2003042204A1 (fr) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Derive d'amine
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2004006921A1 (fr) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited Procede de production d'une preparation recouverte
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
US7976853B2 (en) 2003-01-29 2011-07-12 Takeda Pharmaceutical Company Limited Process for producing coated preparation
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation

Also Published As

Publication number Publication date
RU2359661C2 (ru) 2009-06-27
EP1677792A1 (fr) 2006-07-12
US20060223870A1 (en) 2006-10-05
HUE028576T2 (en) 2016-12-28
NO340294B1 (no) 2017-03-27
KR20100012105A (ko) 2010-02-05
GEP20084570B (en) 2008-12-25
ES2556244T3 (es) 2016-01-14
KR20060061383A (ko) 2006-06-07
ZA200602056B (en) 2007-05-30
PT1677792E (pt) 2016-02-09
JO3106B1 (ar) 2017-09-20
PE20050923A1 (es) 2005-12-26
TW200524641A (en) 2005-08-01
DK1677792T3 (en) 2015-12-14
CN1874774A (zh) 2006-12-06
AR046210A1 (es) 2005-11-30
CA2540225C (fr) 2012-03-06
SI1677792T1 (sl) 2016-02-29
MXPA06004639A (es) 2006-06-27
WO2005041962A1 (fr) 2005-05-12
NZ546337A (en) 2009-03-31
AU2004285354A1 (en) 2005-05-12
PL1677792T3 (pl) 2016-05-31
BRPI0414979A (pt) 2006-11-21
CA2540225A1 (fr) 2005-05-12
NO20062515L (no) 2006-07-31
RU2006118786A (ru) 2007-12-10
TWI339586B (en) 2011-04-01
EP1677792B1 (fr) 2015-11-18
IL174201A (en) 2011-04-28
KR100952090B1 (ko) 2010-04-13
IL174201A0 (en) 2006-08-01
AU2004285354B2 (en) 2009-09-17
CN1874774B (zh) 2011-04-13
HRP20151447T1 (hr) 2016-02-12
US7700128B2 (en) 2010-04-20
CY1117176T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
MA27205A1 (fr) Preparations d'insuline acides presentant une stabilite amelioree
EP1259494A4 (fr) Acides aryloxyacetiques utilises en cas de diabete et de troubles lipidiques
IL174201A0 (en) Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
EP1456347A4 (fr) Anticorps se liant a blys selon un mode immunospecifique
NO20040178L (no) Farmasoytisk formulering innebefattende en protonpumpeinhibitor og syrenoytraliserende midler
EP1698640A4 (fr) Methode de stabilisation d'anticorps et preparation d'anticorps de type solution stabilisee
EP1516056A4 (fr) Sequences d'acides nucleiques associees a la thioesterase et methodes d'utilisation pour la production de plantes presentant une teneur en acides gras modifiee
EP1830816A4 (fr) Forme galenique solide comprenant un inhibiteur de la pompe a protons et supension realisee a partir de la ladite galenique
NO20054555D0 (no) Farmasoytiske preparater som omfatter syrestabilisert insulin
IL174947A0 (en) Site-specific incorporation of redox active amino acids into proteins
EP1218000A4 (fr) Acides gras nitro et thia en tant qu'agents anticancereux
CY2006002I2 (el) Αυτογαλακτωματοποιος σχηματισμος για οξυφορες λιποφυλικες ενωσεις
NO20021205L (no) Faste lipid formuleringer
PL372616A1 (en) Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity
MA27031A1 (fr) Composition pharmaceutique comprenant un inhibiteur de lipase et un ester d'acide gras de saccharose
EP1695956A4 (fr) Compose d'acide carboxylique cyclique et ses utilisations
EP1454629A3 (fr) Composé insulinotrophe basé sur préproglucagone
EP1482937A4 (fr) Nouveaux tyloindicines et composes s'y rapportant, compositions pharmaceutiques et methodes
PL373315A1 (en) Preparations containing diformates and short-chain carboxylic acids
EP1301203A4 (fr) Vaccin comprenant comme agent actif un manno-olisaccharide d'acyl-glyceryl-phosphatidylinositol immunogene
ZA200506750B (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluroanilino) phenylacetic acid
EP1533847A4 (fr) Dispositif d'imagerie solide
ATE349459T1 (de) Polymorph b eines bekannten thiophencarbonsäuredodecahydrocyclopenta(a)phen ntrenylesters
EP1436252A4 (fr) Analogues d'acides gras hydroxysulfoniques
HUP0105151A3 (en) Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes